Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.

Morphosys AG - ADR

Company Announces Successful Completion of Tender Offer   Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") for $34.00 per share, net to the seller in cash, without interest and subject to any applicable withholding of taxes. The tender offer expired at one minute after 11:59 p.m.

MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology

CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical trial of pelabresib (CPI-0610) in myelofibrosis (MF) were published online in association with the European Hematology Association (EHA) annual meeting. The data in these posters are based on a data cutoff of September 29, 2020 from the MANIFEST Phase 2 clinical trial and reflect an analysis of pelabresib clinical and translational activity.

Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib

NEW YORK, June 4, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Constellation Pharmaceuticals, Inc. ("CNST" or the "Company") ( CNST ) relating to its proposed acquisition by MorphoSys AG (MOR). Under the terms of the agreement, CNST shareholders will receive $34.00 in cash per share they own.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Constellation Pharmaceuticals, Inc. - CNST

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today summarized in a poster presentation preliminary data from the ongoing Phase 1/2 trial of CPI-0209, a novel, second-generation, small molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2). These data were published online in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting, and show comprehensive target engagement and durable exposure of CPI-0209. Anti-tumor activity of CPI-0209 in pre-clinical models was demonstrated across several advanced hematologic and solid tumor types.

Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting

The small drugmaker is being acquired by MorphoSys.

Why Constellation Pharmaceuticals Stock Was Crushing It This Week

NEW YORK, June 2, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Constellation Pharmaceuticals, Inc. ("Constellation" or the "Company") (NASDAQ: CNST) in connection with the proposed acquisition of the Company by MorphoSys AG ("MorphoSys") (FSE: MOR; NASDAQ: MOR). The transaction is structured as an all-cash tender offer pursuant to which the Company's shareholders will receive $34.00 for each share of Constellation common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Constellation Pharmaceuticals, Inc.

The company is being acquired by MorphoSys.

Why Constellation Pharmaceuticals Stock Is Skyrocketing Today

MILWAUKEE, June 2, 2021 /PRNewswire/ -- Ademi LLP is investigating Constellation (Nasdaq: CNST) for possible breaches of fiduciary duty and other violations of law in its transaction with MorphoSys. Click here to learn how to join the action: https://www.ademilaw.com/case/constellation-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Constellation Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with MorphoSys

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) to MorphoSys AG for $34.00 per share in cash is fair to Constellation shareholders. Halper Sadeh encourages Constellation shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation

Constellation Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Constellation Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CNST

Constellation Pharmaceuticals Inc (NASDAQ: CNST) is trading higher Wednesday morning after an announcement that MorphoSys AG (NASDAQ: MOR) will acquire the company. What Happened: Constellation and MorphoSys entered into a definitive agreement in which MorphoSys will acquire Constellation for $34 per share, which represents a total equity value of $1.7 billion.

Why Constellation Pharmaceuticals Is Soaring Today

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) ("Constellation" or the "Company") breached their fiduciary duties in connection with the proposed sale of the Company to MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys").   On June 2, 2021, Constellation announced that it had entered into a definitive merger agreement with MorphoSys.

(CNST Alert) Johnson Fistel Investigates Proposed Sale of Constellation Pharmaceuticals; Are Shareholders Getting a Fair Deal?

The stock price of Constellation Pharmaceuticals Inc (NASDAQ: CNST) increased by over 60% pre-market. This is why it happened.

CNST Stock Price: Over 60% Increase Pre-Market Explanation

MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) ("Constellation") whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat) of MorphoSys, as well as the Board of Directors of Constellation and is expected to close in the third quarter of 2021.

MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

PLANEGG/MUNICH, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) (“Constellation”) today announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the management board (Vorstand) and the supervisory board (Aufsich

MorphoSys to Acquire Constellation Pharmaceuticals

CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference. Jigar Raythatha, president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference at 3:00 PM EDT on June 3. Live audio webcast of Mr. Raythatha's presentation and archives for replay will be available on the Investor Relations section of Constellation's website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replays will be available for 90 days following the live presentation.

Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q1 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its first-quarter 2021 financial results. The Company also provided updates on its product candidates pelabresib and CPI-0209.

Constellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter 2021 results and provide a business update. The event will be webcast live and can be accessed on the Investor Relations section of Constellation's website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 8798968.

Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q4 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter 2020 financial results and provided a business update.

Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results

CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference. Jigar Raythatha, CEO, will present at the 10th Annual SVB Leerink Global Healthcare Conference at 3:40 PM EDT on February 26. Live audio webcast of Mr. Raythatha's presentations and archives for replay will be available on the Investor Relations section of Constellation's website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replays will be available for 90 days following the live presentation.

Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on February 24, 2021, to discuss its fourth quarter 2020 results and provide a business update. The event will be webcast live and can be accessed on the Investor Relations section of Constellation's website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 6971724.

Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results

Aurinia Pharmaceuticals

AstraZeneca

Regeneron Pharmaceuticals

AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister also said he expects the EU to approve the company's COVID-19 vaccine on Friday.

Why Aurinia Pharma, AstraZeneca And More Are Trading Higher Today

CNST's CPI-0610 has excellent Phase 2 data in MF. Its SVR35 and TSS50 data compares favourably with other drugs in development and with Jakafi.

Constellation Pharma: CPI-0610 Is Well-Differentiated In The Myelofibrosis Treatment Development Pipeline

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for building and leading the Company's commercial organization and pre-launch preparations in support of CPI-0610, which has the potential to be a disease-modifying therapy for patients living with myelofibrosis.

News for Constellation Pharmaceuticals Inc Stock (CNST)